125 related articles for article (PubMed ID: 9681299)
1. Soluble interleukin-2 receptors (sIL-2R) in ovarian cancer patients: changes in sIL-2R after surgery as a prognostic factor?
Gebauer G; Rieger M; Jäger W; Lang N
Int J Biol Markers; 1998; 13(1):45-7. PubMed ID: 9681299
[No Abstract] [Full Text] [Related]
2. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer.
Hurteau JA; Woolas RP; Jacobs IJ; Oram DC; Kurman CC; Rubin LA; Nelson DL; Berchuck A; Bast RC; Mills GB
Cancer; 1995 Nov; 76(9):1615-20. PubMed ID: 8635066
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble interleukin-2 receptor assay in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Fanucchi A; Annicchiarico C; Facchini V; Bianchi R
Tumour Biol; 1993; 14(5):303-9. PubMed ID: 8235309
[TBL] [Abstract][Full Text] [Related]
4. Clinical implication of serum sIL-2R levels in ovarian cancer.
Wang S; Cai G; Lu Y
J Tongji Med Univ; 1998; 18(2):126-8. PubMed ID: 10806842
[TBL] [Abstract][Full Text] [Related]
5. High serum and ascitic soluble interleukin-2 receptor alpha levels in advanced epithelial ovarian cancer.
Barton DP; Blanchard DK; Michelini-Norris B; Nicosia SV; Cavanagh D; Djeu JY
Blood; 1993 Jan; 81(2):424-9. PubMed ID: 8422462
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
7. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
8. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors in patients with solid tumors are not correlated.
Lissoni P; Rizzo V; Barni S; Rescaldani R; Rovelli F; Biondi A; Archili C; Frigerio F; Tancini G
Int J Biol Markers; 1989; 4(3):170-3. PubMed ID: 2614085
[TBL] [Abstract][Full Text] [Related]
12. Serum soluble interleukin-2 receptors in epithelial ovarian cancer patients.
Pavlidis NA; Bairaktari E; Kalef-Ezra J; Nicolaides C; Seferiadis C; Fountzilas G
Int J Biol Markers; 1995; 10(2):75-80. PubMed ID: 7561242
[TBL] [Abstract][Full Text] [Related]
13. The Diagnostic and Prognostic Value of sIL-2R as an Immune Biomarker in Head and Neck Cancers.
Gross M; Meirovich A; Rachmut J; Kalichman I; Peretz T; Eliashar R; Barak V
Anticancer Res; 2016 Aug; 36(8):4347-52. PubMed ID: 27466555
[TBL] [Abstract][Full Text] [Related]
14. The significance of serum levels of soluble interleukin-2 receptor in patients undergoing maintenance hemodialysis.
Chen X; Li Y; Ding X; Zou J; Shen B; Liu Z; Lv W; Cao X; Xiang F
Ren Fail; 2020 Nov; 42(1):419-427. PubMed ID: 32401100
[No Abstract] [Full Text] [Related]
15. Soluble interleukin 2 receptor in lung cancer. An indirect marker of tumor activity?
Buccheri G; Marino P; Preatoni A; Ferrigno D; Moroni GA
Chest; 1991 Jun; 99(6):1433-7. PubMed ID: 2036827
[TBL] [Abstract][Full Text] [Related]
16. Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications.
Viviani S; Camerini E; Bonfante V; Santoro A; Balzarotti M; Fornier M; Devizzi L; Verderio P; Valagussa P; Bonadonna G
Br J Cancer; 1998 Mar; 77(6):992-7. PubMed ID: 9528846
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of sIL-2R levels in B-cell lymphomas.
Yoshida N; Oda M; Kuroda Y; Katayama Y; Okikawa Y; Masunari T; Fujiwara M; Nishisaka T; Sasaki N; Sadahira Y; Mihara K; Asaoku H; Matsui H; Seto M; Kimura A; Arihiro K; Sakai A
PLoS One; 2013; 8(11):e78730. PubMed ID: 24236041
[TBL] [Abstract][Full Text] [Related]
18. Analysis of interleukin-2/interleukin-2 receptor system in advanced non-small-cell lung cancer.
De Vita F; Turitto G; di Grazia M; Frattolillo A; Catalano G
Tumori; 1998; 84(1):33-8. PubMed ID: 9619711
[TBL] [Abstract][Full Text] [Related]
19. The in vitro effect on T cell function of soluble IL-2Ralpha from advanced ovarian cancer ascites.
Elg SA; Hill RB; Heldman L; Ramakrishnan S
Gynecol Oncol; 1997 Jul; 66(1):133-7. PubMed ID: 9234933
[TBL] [Abstract][Full Text] [Related]
20. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
